Education
About Us
Working with TipRanks
Follow Us
Jane Bell Insider Profile
11 Followers
Jane Bell, Director at Amplia Therapeutics, holds 3.66M shares in Amplia Therapeutics (Ticker: INNMF), holds 622.49K shares in Mesoblast Limited (Ticker: MEOBF). Most recently, Jane Bell Bought ― shares of Amplia Therapeutics on Sep 08, 2025 for an estimated value of $30.00K.
Profitable Transactions
3 out of 11 Profitable Transactions
Average Return
+68.30%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Jane Bell holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Buy
Date:Dec 28, 2023 - Dec 28, 2024
Return:+800.00%
The most profitable trade made by Jane Bell
Jane Bell's Trading History
Amplia Therapeutics
Sep 08, 2025
Director
Informative Buy
30.00K
$366.18K
Mesoblast Limited
Mar 07, 2025
Director
Informative Buy
200.00K
$995.99K
List of latest transactions for each holding click on a transaction to see Jane Bell's performance on stock
You May Also Like
Jane Bell insider profile FAQ
What is the percentage of profitable transactions made by Jane Bell?
The percentage of profitable transactions made by Jane Bell is 27%.
What is the average return per transaction made by Jane Bell?
The average return per transaction made by Jane Bell is 68.30%.
What stocks does Jane Bell hold?
Jane Bell holds: INNMF, MEOBF stocks.
What was Jane Bell’s latest transaction?
Jane Bell latest transaction was an Informative Buy of $30.00K.
What was Jane Bell's most profitable transaction?
Jane Bell’s most profitable transaction was an Informative Buy of MEOBF stock on December 28, 2023. The return on the trade was 800.00%.
What is Jane Bell's role in Amplia Therapeutics?
Jane Bell's role in Amplia Therapeutics is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.